Illustrative image – not actual.The company intends to grow its revenue and operate profits in FY19 and is banking on growth drivers such as speciality pharmaceuticals, active pharmaceutical ingredient (API) and generics and life science ingredients.
In the life science ingredients segment, the company intends to register a growth in revenues from new product launches, new orders, new capacities coming on stream and de-bottlenecking of the existing plants.
The company is increasing capacity in solid dosage formulations at Roorkee, Uttarakhand which is expected to be completed in Q4/FY19. It is also taking various initiatives to reduce cost from higher efficiencies and also input material cost optimisation.
The company has a pipeline of at least five products in radio-pharmaceuticals business which it expects to file and launch in the next few years.
